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A series of tricyclic penciclovir (PCV) and hydroxybutylguanine (HBG) derivatives 
have been prepared with enhanced lipophilicity following an efficient synthetic route. 
All the novel tricyclic derivatives were evaluated for inhibitory activity against herpes 
simplex virus 1 and 2 (HSV-1, HSV-2) and thymidine kinase deficient (ACV resistant) 
HSV-1. The tricyclic HBG derivatives were devoid of inhibitory activity however 
several of the tricyclic PCV derivatives showed promising antiviral activity, in 
particular 9g (R=4-MeO-C6H4) displayed good inhibitory activity (HSV-1 EC50 1.5 
M, HSV-2 EC50 0.8 M) and retained inhibitory activity in HSV-1 TK- cells (EC50 
0.8 M). Computational docking experiments supported the biological data observed 
and this preliminary study provides useful data for further development of tricyclic 
acyclic nucleoside derivatives with improved lipophilicity and retention of activity in 
HSV-1 TK deficient strains. Also, the new tricyclic derivatives were evaluated against 
a broad range of other DNA and RNA viruses, but were found to be inactive at subtoxic 
concentrations. In addition, weak to moderate cytostatic effect was observed for the 
new compounds. 
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modelling. 
 
 
 
1.Introduction 
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The herpes simplex virus (HSV), like all herpes viruses, establishes lifelong latency 
following a primary infection. HSV-associated diseases can range from mild orolabial 
ulcers (cold sores) to severe encephalitis.1 Herpes simplex viruses are categorised into 
two types: HSV-1, which is mainly transmitted through oral-oral contact resulting 
mainly in cold sores;1 and HSV-2, which is mainly sexually transmitted resulting in the 
most common infection of genital herpes.2 Globally two thirds of the population under 
the age of 50 are estimated to be infected with HSV-1.3 
Herpes simplex encephalitis (HSE) is the most common cause of sporadic fatal viral 
encephalitis, accounting for almost 20% of all cases of encephalitis.4 HSE presents as 
an acute focal necrotising infection of the brain, which, if untreated, has a 70% 
mortality rate.5 The first line treatment of HSE is aciclovir (ACV), administered 
intravenously for 14-21 days, however even when treated, HSE is associated with a 
30% mortality rate and permanent neurological damage.6-8 Limitations of ACV therapy 
for HSE are the development of viral resistance9 and low  CNS uptake.10 
Parent drug Tricyclic derivative 
  
  
 
Figure 1. Parent acyclic nucleosides and tricyclic derivatives 
Tricyclic ACV and ganciclovir (GCV) derivatives (Figure 1) were shown to be 
effective inhibitors of HSV-1 thymidine kinase (TK) and are of interest as they maintain 
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the inhibitory activity against the enzyme and, as they are more lipophilic than the 
current medications, may be valuable agents for the treatment of CNS infections.11-13 
Moreover, these tricyclic compounds were found to exhibit strong intrinsic fluorescent 
properties, which allows for sensitive concentration monitoring and optimal therapeutic 
dosing.11-13 Penciclovir (PCV) and hydroxybutylguanine (HBG) (Figure 1) are the 
carbocyclic analogues of GCV and ACV, respectively.The spectrum of activity of PCV 
against human herpesviruses was found to be similar to that of ACV, however in certain 
circumstances PCV was more active than ACV owing to the higher stability of PCV-
TP in infected cells relative to ACV-TP.14 Also, at concentrations up to 100 µg/mL, it 
was confirmed that PCV, like ACV, was highly selective and subsequently did not 
exhibit any toxicity in cell culture.14 Similarly, HBG is reported to have higher affinity 
for HSV-1 TK than ACV in addition to relatively comparable selectivity for inhibition 
of viral DNA synthesis and good safety profile in cell culture.15 
Application of the tricyclic scaffold modification to PCV and HBG was of interest to 
determine whether antiviral activity was maintained and, importantly, modification of 
the nucleobase moiety with an additional ring may result in beneficial physicochemical 
properties (enhanced lipophilicity, fluorescence) and /or enhanced enzyme binding 
interaction. A library of tricyclic PCV and HBG derivatives (Figure 2) was designed 
and synthesised to evaluate antiviral activity and study structure-activity relationships, 
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Figure 2. Library for the designed tricyclic PCV and HBG nucleosides 
 
2. Results and discussion 
2.1 Chemistry  
PCV (6) and HBG (7) were prepared as previously described by reaction of 2-amino-
6-chloropurine (1) with 5-(2-bromoethyl)-2-phenyl-1,3-dioxane (2)16 or 4-
bromobutylacetate (3)17 with subsequent acid hydrolysis of the protected derivatives 
(4) and (5) (Scheme 1). 
The new tricyclic analogues of PCV and HBG, 3-[4-hydroxy-3-(hydroxymethyl)butyl]-
6-(aryl)-3,5 dihydro-9H-imidazo[1,2-a]purin-9-one (9) and 3-(4-hydroxybutyl)-6-
(aryl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one (10) were obtained upon reaction of 
the sodium salt of PCV (6) and HBG (7), generated in situ on treatment with NaH, and 
the appropriate bromoketone (8) in 38-79 % yield (Table 1). The new compounds were 
purified by flash column chromatography using a gradient eluting mixture of CH2Cl2-
MeOH followed by recrystallisation (Scheme 1). The procedure used for the 
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preparation of the new derivatives mostly followed a previously reported method for 
the preparation of analogously modified guanosine and other tricyclic derivatives.12 
 
 
Scheme 1. Reagents and conditions: (i) K2CO3, 18-crown-6, DMF, r.t. 72 h for synthesis of 4, 
94 %, 16 h for synthesis of 5, 81% (ii) (a) 2M aqueous HCl, 90 oC, 3h (b) 10% aqueous NaOH, 
4 oC 24 h, 77 % (iii) (a) 2M aqueous HCl, THF, 75 oC overnight (b) 10% aqueous NaOH, 4 oC 
24 h, 81% (iv) NaH, DMF, r.t. 6 h, 38-79%. 
 
The tricyclic derivatives showed some sensitivity towards light and air, so were 
protected by wrapping with foil and rapid storage in amber coloured vials. The 6-thien-
2-yl group was highly unstable to light and air and in the case of the PCV derivative 
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decomposed rapidly during collection. Conversely, its HBG congener (10h) was stable 
enough to be collected safely.  
 
Table 1. Yields and mp data for final tricyclic PCV and HBG derivatives 9 and 10 
 
 
 
No. R Yield  
(%) 
m.p. 
(oC) 
No. R Yield 
(%) 
m.p. 
(oC) 
9a 
 
68 212-
214 
10a 
 
61 248-
250 
9b 
 
65 >300 10b 
 
62 288-
290 
9c 
 
62 258-
260 
10c 
 
62 280-
282 
9d 
 
61 112-
114 
10d 
 
67 260-
261 
9e 
 
55 >300 10e 
 
71 292-
293 
9f 
 
38 >300 10f 
 
61 252-
254 
9g 
 
79 202-
203 
10g 
 
69 272-
274 
9h 
 
77 276-
278 
10h 
 
64 246-
247 
9i 
 
68 259-
260 
  
  
9j 
 
75 276-
278 
  
  
 
 
 
2.2 Biological evaluation 
2.2.1 Antiviral activity 
The tricyclic compounds (9 and 10) were screened as inhibitors of HSV using herpes 
simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase 
deficient (aciclovir resistant) herpes simplex virus-1 (HSV-1 TK–KOS ACVr strain) in 
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human embryonic lung (HEL) cells. None of the tricyclic HBG derivatives (10) showed 
any inhibitory activity (EC50>100 M) or cytotoxicity (>100 M) against HSV-1 or 
HSV-2. However, some of the tricyclic PCV derivatives (9) exhibited anti-herpetic 
activity (Table 2). 
 
Table 2. Inhibitory activity of tricyclic PCV derivatives (9) against HSV and 
cytotoxicity data  
 
Compound 
Antiviral activity EC50 (M)a Cytotoxicity (M) 
HSV-1 (KOS) HSV-2 (G) HSV-1 TK- 
KOS ACVr 
Cell Morphology 
(MCC)b 
PCV (6) 0.8 0.2 0.2 >100 
9a >100 >100 >100 >100 
9b 8.9 28 12 >100 
9c >100 >100 >100 >100 
9d >100 >100 >100 >100 
9e 20 31.7 >100 >100 
9f 7.6 2.3 >100 >100 
9g 1.5 0.8 0.8 >100 
9h 76.5 >20 >100 >100 
9i 44.7 40.9 >100 >100 
9j >100 >100 >100 >100 
     
HBG (7) 1.5 2.1 10 >100 
GCV 0.07 0.4 0.8 >250 
CDV 2.0 2 5 >250 
ACV 0.9 0.9 100 >250 
BVDU 0.04 >250 14 >250 
aRequired to reduce virus-induced cytopathogenicity by 50 %. 
bRequired to cause a microscopically detectable alteration of normal cell morphology. 
Aciclovir (ACV), Brivudin (BVDU), Cidofovir (CDV), Ganciclovir (GCV) 
 
Of the newly synthesised tricyclic PCV derivatives, compounds 9a, 9c, 9d and 9j were 
inactive as antiviral agents. Compounds 9h and 9i showed anti-HSV-1 activity only at 
a relatively high concentration (EC50 = 76.5 and 44.7 µM, respectively), compounds 9b 
and 9e showed moderate anti-HSV-1 activity (EC50 = 8.9 and 20.00 µM/mL, 
respectively), whereas 9g and 9f were the most active and were inhibitory to HSV-1 
replication with EC50 = 1.5 and 7.6 µM, respectively. Similar to anti-HSV-1 results, 
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among the synthesised tricyclic PCV compounds, compounds 9g and 9f were the most 
active against the HSV-2 strain and showed marked inhibition (EC50 = 0.8 and 2.3µM, 
respectively). Also, compounds 9b, 9e and 9i showed moderate activity against HSV-
2 strain (EC50 = 28 - 40.9 µM), whereas the remaining compounds did not show any 
activity against the HSV-2 strain. Two compounds, 9b and 9g, retained activity against 
the TK- ACV resistant strain of HSV-1. Compound 9g showed potent inhibitory activity 
against HSV-1 TK- (EC50 = 0.8 µM), whereas compound 9b was moderately active 
against HSV-1 TK- (EC50 = 12 µM). The data suggest that in the case of the resistant 
strain TK-, compounds 9f and 9g are independent of viral TK catalysed phosphorylation 
for antiviral activity and/or may use a different metabolic activation pathway and/or 
display a unique mechanism of antiviral action by the un-metabolised nucleoside 
analogue. 
 
Table 3. Inhibitory activity of tricyclic PCV derivatives (9) against VZV and HCMV 
and cytotoxicity data  
 
Compound 
Antiviral activity EC50 (M)a  Cytotoxicity 
(M) 
VZV TK+ 
Oka strain 
VZV TK- 
07-1 strain 
HCMV 
AD-169 strain 
HCMV 
Davis strain 
Cell Morphology 
(MCC)b 
PCV (6)  3.5 33.4 >100 >100 >100 
9a >100 >100 >100 >100 >100 
9b >100 >100 >100 >100 >100 
9c >100 >100 >100 >100 >100 
9d 63.14 >100 >100 >100 >100 
9e 49.5 100 63.1 76.5 100 
9f 9.6 ≥74.5 >100 >100 >100 
9g 66.87 100 >100 >100 >100 
9h >100 >100 >100 >100 >100 
9i >20 >100 >100 >100 100 
9j 62.8 >100 >100 >100 >100 
      
HBG (7)  76.5 >100 >100 >100 >100 
GCV ND ND 6.5 4.6 >250 
CDV ND ND 0.72 0.87 >250 
ACV 5.0 59.2 ND ND >250 
BVDU 0.037 7.9 ND ND >250 
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aRequired to reduce virus-induced cytopathogenicity (HCMV) or plaque formation (VZV) by 
50 %. 
bRequired to cause a microscopically detectable alteration of normal cell morphology. 
Aciclovir (ACV), Brivudin (BVDU), Cidofovir (CDV), Ganciclovir (GCV). 
ND: not determined. 
 
In addition to HSV all the tricyclic derivatives (9 and 10) were screening against a broad 
range of DNA and RNA viruses including vaccinia virus, adenovirus-2, human 
coronavirus (229E), human cytomegalovirus (HCMV) (AD-169 strain and Davis 
strain), varicella-zoster virus (TK+VZV OKA strain and TK- VZV 07-1 strain), 
vesicular stomatitis virus, Coxsackie virus B4, respiratory syncytial virus, 
parainfluenza-3 virus, reovirus-1, Sindbis virus, Punta Toro virus, yellow fever virus, 
influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus.  Of all the 
compounds, only a few displayed any inhibitory activity < 100 M against VZV and 
HCMV (Table 3): 9e (R = CF3-C6H4-) showed weak inhibitory activity against 
cytomegalovirus AD-169 strain and Davis strain (EC50 = 63.1 µM and 76.5 µM 
respectively) compared with GCV as the reference compound (EC50 = 6.5 µM and 4.6 
µM respectively) and the TK+ VZV Oka strain (EC50= 49.5 µM); 9f (R = HO-C6H4-) 
showed inhibitory activity against varicella-zoster virus TK+VZV OKA strain and TK- 
VZV 07-1 strain (EC50 = 9.6 µM and ≥74.5 µM respectively) compared with ACV as 
the reference compound (EC50 = 5.0 µM and 59.2 µM respectively); 9d and 9j only 
displayed minimal activity against the VZV TK+  strain Oka (EC50 = 63 µM). It should 
be noted that in contrast to HSV, HBG (7) proved inactive against HCMV and poorly 
inhibited the VZV TK+ strain (EC50= 76.5 µM). PCV was not inhibitory to HCMV but 
inhibited VZV with EC50 values comparable with those of ACV, i.e. 3.5 and 33.4 µM, 
respectively for TK+ and TK- VZV strains (Table 3). 
2.2.2 Cytostatic activity 
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The new compounds were screened for their potential cytostatic activity against eight 
human cancer cell lines. The 50% cytostatic inhibitory concentration (IC50) causing a 
50% decrease in cell proliferation was determined against retina (non-cancerous) 
hTERT RPE-1, pancreatic adenocarcinoma Capan-1, chronic myeloid leukaemia Hap1, 
lung carcinoma NCI-H460, acute lymphoblastic leukaemia DND-41, acute myeloid 
leukaemia HL-60, chronic myeloid leukaemia K-562 and non-Hodgkin lymphoma Z-
138 (Table 4).  
 
Table 4: Cytostatic activity results of compounds 9 and 10 
 
No. 
IC50 (M)a 
hTERT 
RPE-1 
Capan-
1 
Hap1 
NCI-
H460 
DND-
41 
HL-
60 
K-
562 
Z-138 
PCV >100 93.0 >100 >100 >100 >100 >100 >100 
9a 78.6 58.3 >100 >100 >100 >100 >100 >100 
9b >100 82.8 >100 >100 >100 >100 >100 >100 
9c >100 84.8 >100 >100 >100 >100 >100 >100 
9d >100 >100 >100 >100 >100 >100 >100 >100 
9e 51.5 17.2 37.8 12.5 56.5 55.3 >100 76.1 
9f >100 >100 >100 >100 >100 >100 >100 >100 
9g >100 >100 >100 >100 >100 >100 >100 >100 
9h >100 >100 >100 95.4 >100 >100 >100 >100 
9i >100 78.8 >100 >100 >100 >100 >100 >100 
9j 16.9 46.4 44.0 47.2 90.4 63.3 >100 >100 
HBG >100 72.7 >100 >100 >100 >100 >100 >100 
10a >100 69.1 >100 >100 >100 >100 >100 >100 
10b >100 56.1 >100 55.5 >100 >100 >100 >100 
10c >100 64.4 >100 >100 >100 >100 >100 >100 
10d >100 78.9 >100 >100 >100 >100 >100 >100 
10e >100 36.1 63.8 52.5 >100 >100 >100 >100 
10f >100 98.9 >100 >100 >100 >100 >100 >100 
10g >100 92.8 >100 >100 >100 >100 >100 >100 
10h >100 >100 >100 >100 >100 >100 >100 >100 
Docetaxel 25.0 0.95 1.19 0.89 1.63 1.94 3.00 3.00 
Etoposide 0.23 0.15 0.04 1.35 0.06 0.03 0.54 1.06 
Stauroporine 0.25 0.66 3.55 11.50 21.5 9.24 23.10 21.50 
a50% Inhibitory concentration or compound concentration required to inhibit cell proliferation by 50%.  
hTERT RPE-1 retina (non cancerous); Capan-1 pancreatic adenocarcinoma; Hap1 chronic myeloid 
leukemia; NCI-H460 lung carcinoma; DND-41 acute lymphoblastic leukemia; HL-60 acute myeloid 
leukemia; K-562 chronic myeloid leukemia; Z-138 non-Hodgkin lymphoma 
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Among the tricyclic PCV derivatives compounds 9e(R = CF3-C6H4-) and 9j(R = C6H5-
O-C6H4-) showed moderate cytostatic activity against at least six cell lines in the range 
of 12.5 - 76.1 µM and 16.9 - 90.4 µM respectively. The tricyclic HBG derivatives (10) 
were generally inactive or displayed very weak cytostatic activity. Of the tricyclic HBG 
derivatives the trifluoromethyl aryl derivative of HBG 10e (R = CF3-C6H4-) was the 
most effective against the range of cancer cell lines. Proliferation of the pancreatic 
adenocarcinoma Capan-1 cell line was slightly inhibited by most of the new tricyclic 
compounds as well as the parent compounds PCV and HBG (Table 4).  
2.3 Molecular Modelling  
Molecular modelling of the compounds was performed using Molecular Operating 
Environment (MOE) software18 and the crystal structure of HSV-1 thymidine kinase 
co-crystallised with PCV (PDB 1KI3)19 and 9-(4-hydroxybutyl)-N2-phenylguanine 
(HBPG) (PDB 1QHI)20. 
The crystal structures of HSV-1 TK do not include an ATP molecule and a sulphate ion 
is observed at the supposed position of the β-phosphate of ATP.19,20 Therefore, the 
distance between OH of the acyclic chain and SO4 was measured to give an idea about 
the proper orientation of the ligand within the active site and the possibility for the 
compound acyclic OH to be phosphorylated by the enzyme. Results indicated that PCV 
analogues 9a-j display distances in the range of 2.73-6.82 Å compared with PCV (4.61 
Å). The HSV-1 TK pocket is predominately lipophilic with several regions of 
hydrophilicity. PCV and HBPG probe the space of the enzyme active site in a manner 
that maintains both the base moiety (guanine) and the acyclic sugar hydroxyl groups in 
a good geometry. 
 
 
A 
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B 
 
 
 
 
 
Figure 3. 2D 
Ligplots 
illustrating the 
amino acids in 
HSV-1 TK active 
site involved in 
binding 
interactions with 
(A) PCV and (B) 
HBPG 
 
Overall docking results revealed some important interactions for the binding of the 
reference ligands PCV and HBPG within the active site (Figure 3). The base moiety is 
lying in a location that stacks with Tyr172 and makes hydrophobic interactions with 
the amino acid residues; Tyr172, Met128, His58. Also, H-bond interactions are 
observed between the carbonyl group as well as the top ring nitrogens with Arg176 and 
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Gln125. The acyclic sugar moiety forms two important H-bond interactions with amino 
acid residues Arg163 and Glu83 (Figure 3).  
 
Figure 4. Docking of representative tricyclic PCV derivative 9f (cyan) in the HSV-1 TK active 
site compared with PCV (magenta). 
 
The tricyclic PCV compounds lead to interactions with additional amino acids and, 
amongst the new compounds, the observed interactions of the most active compounds 
9f and 9g (R= 4-HO-C6H4, and 4-MeO-C6H4) closely mimic the interactions observed 
with PCV binding. However, rather than Gln125, the 4-HO-C6H4 and 4-MeO-C6H4 
form a H-bond interaction with Ala168 or water-bridged H-bonds with Ala168 and 
Gln125 (Figure 4). The moderately active fluoro substituted analogues, 9b and 9e, 
showed almost similar binding modes, although the small fluoro substituent was better 
docked within the base pocket with the tricyclic moiety forming π-π interaction with 
Tyr172. 
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As the tricyclic purine moiety is longer than the guanine base of PCV, the orientation 
of the 6-arylgroup has an impact on the geometry of the acyclic hydroxyl groups and 
hence the stability of the formed complex for further phosphorylation. PCV analogues 
9h, 9i and 9j with relatively more bulky ether moieties (4-EtO-C6H4, 3-OCH2O-4-
C6H3and 4-C6H5O-C6H4) formed weak interactions within the acyclic sugar binding 
pocket. In addition a steric clash was observed in case of compound 9j.The steric effect 
might consequently diminish or abolish their complex stability. 
 
A B 
Figure 5: Docking of HBG analogues 10a-h showing two different orientations adopted by the 
compounds on binding within the HSV-1 TK active site. 
 
Analysis of the docked HBG analogues 10a-h compared with HBPG suggests that the 
ligand likely competes between two different binding orientations within the active site. 
In one orientation the tricyclic base moiety stacks with Tyr172 with the carbonyl group 
forming a H-bond from Gln125, while the acyclic hydroxyl group is situated 5.73-7.13 
Å from the sulphate group (HPBG 5.66 Å) and donates a H-bond to Glu83 and/or 
accepts water bridged H-bonds from Arg163, Glu83, Arg222 and Lys62. Also, Arg176, 
in some derivatives, donates a H-bond to N-1 (Figure 5A). In the other orientation the 
tricyclic structure is lying in a location that allows a stacking interaction with His58 
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and the carbonyl group is being upturned to accept a H-bond from Arg163 and /or 
water-bridged H-bonds from Arg163, Glu83, Arg222 and Lys62. In contrast, the same 
acyclic hydroxyl group in the second ligand orientation is 12.75 Å away from the 
sulphate compared with the former orientation where it accepts a H-bond from Arg176 
(Figure 5B).  In both orientations no contribution in ligand binding was observed for 
the 6-aryl group resulting in more flexibility and weaker binding of the whole 
compound within the active site.  
 
3. Conclusion 
Comparing antiviral activity to compound structure provides an insight into which 
functional groups may be beneficial towards HSV-1 inhibitory activity. 
 
Figure 6: Summary for SAR of the new tricyclic PCV compounds 
 
The SAR study suggested that a di-hydroxyl acyclic sugar moiety was essential for the 
activity. For the PCV derivatives, activity was only retained in those that have a 
hydrogen bond forming group on the tricyclic ring, however the size of the hydrogen 
bond forming group is limited with larger groups inducing a steric effect that exhibits 
an apparent impact on activity, which was supported by molecular docking (Figure 6). 
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The new tricyclic analogues of PCV and HBG are the carbocyclic analogues of the 
previously reported tricyclic analogues of GCV and ACV11,12, (Figure 1). For both the 
tricyclic ACV and GCV derivatives, inhibitory activity against HSV-1 and HSV-2 were 
generally comparable, however this activity was not retained in HSV-1 TK–KOS ACVr 
strain.  Replacing oxygen in the acyclic chain of the tricyclic ACV analogues by carbon 
in the new tricyclic HBG derivatives abolished their activity, highlighting the 
preference of O rather than CH2 in the acyclic chain of the tricyclic guanine derivative. 
In the case of the tricyclic PCV derivatives the activity generally decreased noticeably 
however activity was retained only in the tricyclic PCV derivatives with R=6-(4-MeO-
C6H4) and R=6-(4-HO-C6H4) and R=6-(4-F-C6H4) groups as discussed in the present 
study. Importantly, for two of the tricyclic PCV derivatives with R=6-(4-MeO-C6H4) 
and R=6-(4-F-C6H4) groups activity was retained in the ACV resistant HSV-1 TK–KOS 
strain, which was not observed for the tricyclic GCV compounds11,12. 
This preliminary study provides useful data for further development of tricyclic acyclic 
nucleoside derivatives with improved lipophilicity and retention of activity in TK 
deficient strains.  
 
4. Experimental 
4.1 General Experimental 
All reagents and solvents were of general purpose or analytical grade and purchased from 
Sigma-Aldrich Ltd, Fisher Scientific, Fluka and Acros. 1H, 13C and 19F NMR spectra were 
recorded with a Bruker Avance DPX500 spectrometer operating at 500, 125 and 470 
MHz respectively, with Me4Si as internal standard. Elemental analysis was performed 
(for compounds 10e and 10g) by MEDAC Ltd (Chobham, Surrey, UK). High resolution 
mass spectra (HRMS) were determined (for compounds 9a-j, 10a-d, 10f, and 10h) at 
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the EPSRC National Mass Spectrometry Facility at Swansea University and Medac Ltd 
(Chobham, Surrey, UK), using ESI (Electrospray Ionisation). Flash column 
chromatography was performed with silica gel 60 (230-400 mesh) (Merck) and TLC 
was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were 
visualised by illumination under UV light (254 nm). Melting points were determined 
on an electrothermal instrument and are uncorrected. All solvents were dried prior to 
use and stored over 4 Å molecular sieves, under nitrogen. All the compounds were ≥ 
95% pure. 
The following compounds were prepared as previously described: PCV (6),16 HBG 
(7),17 and the bromoketones (8).21-25 
4.2 Chemistry 
4.2.1. General method for the synthesis of tricyclic PCV and HBG derivatives 9 and 
10.To a suspension of penciclovir (6) or hydroxybutylguanine (7) (0.2 g, 0.8 mmol or 
0.9 mmol, respectively) in dry dimethylformamide (16 mL), sodium hydride (60% 
suspension in mineral oil, 1.2 eq.) was added and the reaction stirred at room 
temperature (21 ̊C) for 1.5 h. Bromoketone (8) (1.3 eq.) was then added and the reaction 
stirred for 6 h. Aqueous ammonia (25% solution 5 mL) was added to quench the 
reaction, which was concentrated under reduced pressure and the residual oil purified 
by flash column chromatography using gradient elution (CH2Cl2-MeOH). The obtained 
products were recrystallised from a mixture of CH2Cl2 and MeOH. 
4.2.1.1. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-phenyl-3,5-dihydro-9H-imidazo[1,2-
a]purin-9-one(9a). Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-1-
(phenyl)ethan-1-one (8a) (0.21 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 90:10 v/v to give the product as a 
white solid. Yield: 0.19 g (68%), m.p. 212-214 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
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0.26. 1H-NMR (DMSO-d6): δ 1.51 (septet, 1H, J=6.0 Hz, H-3'), 1.82 (q, 2H, J=7.0 Hz, 
H-2'), 3.40 and 3.47 (two quint, 4H, J=5.4Hz, H-4'), 4.17 (t, 2H, J= 7.5Hz, H-1'), 4.48 
(t, 2H, J= 5.3 Hz, 2 x OH), 7.39 (t, 1H, J=7.0 Hz, H-4''), 7.49 (t, 2H, J= 7.7 Hz, H-3" 
and H-5"), 7.91 (d, 2H, J= 7.4 Hz, H-2'' and H-6''), 7.95 (s, 1H, H-2), 8.21 (s, 1H, H- 
7), 13.07 (br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 29.1 (C-2'), 41.3 (C-3'), 42.0 (C-1'), 
61.8 (C-4'), 103.6 (C-7), 115.9 (C-9a), 125.4 (C-4''), 128.4 (C-6), 129.2 (C-2" and C-
6"), 129.4 (C-1''), 129.5 (C-3'' and C-5''), 139.0 (C-2), 146.9 (C-4a), 150.6 (C-3a), 151.7 
(C-9). [ESI-HRMS] calculated for C18H20N5O3: 354.1561 [M+H]+. Found: 354.1562 
[M+H]+. 
4.2.1.2. 6-(4-Fluorophenyl)-3-(4-hydroxy-3-(hydroxymethyl)butyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (9b).Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-1-
(4-fluorophenyl)ethanone (8b) (0.23 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 98:2 to 91:9 v/v to give the product as a 
white solid. Yield: 0.19 g (65%), m.p. > 300 oC, TLC (CH2Cl2-MeOH 9:1 v/v) Rf 0.49. 
1H-NMR (DMSO-d6): δ 1.50 (septet, 1H, J=6.0 Hz, H-3'), 1.81 (q, 2H, J=7.0 Hz, H-
2'), 3.38 and 3.46 (two quint, 4H, J=5.4 Hz, H-4'), 4.17 (t, 2H, J= 7.5 Hz, H-1'), 4.48 
(t, 2H, J=5.25 Hz, 2 x OH), 7.34 (t, 2H, JHF= 8.8 Hz, H-3" and H-5"), 7.97 (s, 1H, H-
2), 7.98 (dd, 2H, JHH,JHF= 6.0, 8.5 Hz, H-2'' and H-6''), 8.21 (s, 1H, H-7), 13.10 (br.s, 
1H, H-5). 13C-NMR(DMSO-d6): δ 29.1 (C-2'), 41.3 (C-3'), 42.0 (C-1'), 61.8 (C-4'), 
103.6 (C-7), 116.1 (C-9a), 116.6 (d, 2C, JCF =22 Hz, C-3'' and C-5''), 125.1 (C-1''), 
127.7 (d, 2C, JCF = 8.0 Hz, C-2'' and C-6"), 128.5 (C-6), 139.6 (C-2), 146.8 (C-4a), 
150.6 (C-3a), 151.8 (C-9), 162.6 (d, 1C, JCF = 245 Hz, C-4''). 19F-NMR(DMSO-d6): δ-
112.40. [ESI-HRMS] calculated for C18H19N5O3F: 372.1472 [M+H]+. Found: 372.1483 
[M+H]+. 
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4.2.1.3. 6-(4-Chlorophenyl)-3-(4-hydroxy-3-(hydroxymethyl)butyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one, (9c).Prepared from PCV (0.2 g, 0.8  mmol) and 2-bromo-
1-(4-chlorophenyl)ethanone (8c) (0.24 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 90:10 v/v to give the product as a 
white solid. Yield: 0.19 g (62%), m.p. 258-260 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
0.29. 1H-NMR (DMSO-d6): δ 1.50 (septet, 1H, J=6.0 Hz, H-3'), 1.81 (q, 2H, J=7.0 Hz, 
H-2'), 3.38 and 3.46 (two quint, 4H, J=5.5 Hz, H-4'), 4.17 (t, 2H, J= 7.5 Hz, H-1'), 4.48 
(t, 2H, J= 5.2 Hz, 2 x OH), 7.56 (d, 2H, J=8.6 Hz, H-2" and H-6"), 7.94 (s, 1H, H-2), 
7.95 (d, 2H, J=8.6 Hz, H-3" and H-5"), 8.29 (s, 1H, H-7), 13.13 (br.s, 1H, H-5). 13C-
NMR (DMSO-d6): δ 29.1 (C-2'), 41.3 (C-3'), 42.0 (C-1'), 61.8 (C-4'), 104.3 (C-7), 116.0 
(C-9a), 127.2 (C-2" and C-6"), 127.5 (C-1"), 128.4 (C-6), 129.6 (C-3" and C-5"), 133.7 
(C-4"), 139.5 (C-2), 146.9 (C-4a), 150.7 (C-3a), 151.8 (C-9). [ESI-HRMS] calculated 
for C18H19N5O3Cl: 388.1176 [M+H]+. Found: 388.1187 [M+H]+. 
4.2.1.4. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-(p-tolyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (9d).Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-1-
(p-tolyl)ethanone (8d) (0.22 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 100:0 to 85:15 v/v to give the product as 
a white solid. Yield: 0.18 g (61%), m.p. 112-114 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
0.47. 1H-NMR (DMSO-d6): δ 1.50 (septet, 1H, J=6.0 Hz, H-3'), 1.82 (q, 2H, J=7.0 Hz, 
H-2'), 2.34 (s, 3H, CH3), 3.39 and 3.46 (two quint, 4H, J=5.4 Hz, H-4'), 4.17 (t, 2H, J= 
7.5 Hz, H-1'), 4.48 (t, 2H, J= 5.3 Hz, 2 x OH), 7.28 (d, 2H, J=8.0 Hz, H-3" and H-5"), 
7.79 (d, 2H, J=8.0 Hz, H-2" and H-6"), 7.95 (s, 1H, H-2), 8.13 (s, 1H, H-7), 13.01 (br.s, 
1H, H-5). 13C-NMR (DMSO-d6): δ 21.3 (CH3), 29.1 (C-2'), 41.3 (C-3'), 44.0 (C-1'), 
61.8 (C-4'), 103.0 (C-7), 116.0 (C-9a), 125.4 (C-3" and C-5"), 125.7 (C-1"), 129.5 (C-
6), 130.0 (C-2" and C-6"), 138.8 (C-4"), 139.5 (C-2), 146.8 (C-4a), 150.6 (C-3a), 151.8 
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(C-9). [ESI-HRMS] calculated for C19H21N5O3Na: 390.1537[M+Na]+. Found: 
390.1533[M+Na]+. 
4.2.1.5. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-(4-(trifluoromethyl)phenyl)-3,5-
dihydro-9H-imidazo[1,2-a]purin-9-one (9e). Prepared from PCV (0.2 g, 0.8 mmol) and 
2-bromo-1-(4-(trifluoromethyl)phenyl)ethanone (8e) (0.28 g, 1.04 mmol) and purified 
by flash column chromatography eluting with CH2Cl2-MeOH 95:5 to 92:8 v/v to give 
the product as a white solid. Yield: 0.18 g (55%), m.p. > 300 oC, TLC (CH2Cl2-MeOH 
95:5 v/v) Rf 0.43. 1H-NMR (DMSO-d6): δ 1.51 (septet, 1H, J= 6.0 Hz, H-3'), 1.82 (q, 
2H, J= 7.0 Hz, H-2'), 3.39 and 3.46 (two quint, 4H, J =5.4 Hz, H-4'), 4.18 (t, 2H, J =7.0 
Hz, H-1'), 4.45 (br s, 2H, 2 x OH), 7.85 (d, 2H, J = 7.8 Hz, H-2" and H-6"), 7.98 (s, 1H, 
H-2), 8.15 (d, 2H, J =7.7 Hz, H-3" and H-5"), 8.42 (s, 1H, H-7), 13.24 (br.s, 1H, H-5). 
13C-NMR (DMSO-d6): δ 29.2 (C-2'), 42.0 (C-3'), 42.3 (C-1'), 61.8 (C-4'), 105.7 (C-7), 
116.1 (C-9a), 124.5 (d, 1C, JCF = 272 Hz, CF3), 126.1(C-2'' and C-6''), 126.4 (d, 2C, 
JCF = 3.8 Hz, C-3'' and C-5''), 128.0 (C-6), 128.5 (q, 1C, JCF = 31.8 Hz, C-4''), 132.6 (C-
1''), 139.7 (C-2), 147.0 (C-4a), 150.8 (C-3a), 151.7 (C-9). 19F-NMR(DMSO-d6): δ-
61.11.[ESI-HRMS] calculated for C19H19N5O3F3: 422.1440 [M+H]+, Found: 422.1430 
[M+H]+.  
4.2.1.6. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-(4-hydroxyphenyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (9f).Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-1-
(4-hydroxyphenyl)ethanone (8f) (0.22 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 90:10 v/v to give the product as a 
pale yellow solid. Yield: 0.11 g (38%), m.p. > 300 oC, TLC (CH2Cl2-MeOH 9:1 v/v) 
Rf 0.25. 1H-NMR (DMSO-d6): δ 1.51 (septet, 1H, J= 6.0 Hz, H-3'), 1.81 (q, 2H, J= 7.0 
Hz, H-2'), 3.38 and 3.45 (two quint, 4H, J =5.4 Hz, H-4'), 4.17 (t, 2H, J=7.0 Hz, H-1'), 
4.47 (br s, 2H, 2 x OH), 6.86 (d, 2H, J =8.7 Hz, H-3" and H-5"), 7.72 (d, 2H, J =8.7 
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Hz, H-2" and H-6"), 7.95 (br s, 2H, H-2 and H-7) 9.87 (br s, 1H, phenolic OH), 12.89 
(br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 29.1 (C-2'), 41.3 (C-3'), 42.0 (C-1'), 61.8 (C-
4'), 101.4 (C-7), 116.0 (C-9a), 116.3 (C-3'' and C-5''), 119.2 (C-1''), 127.1 (C-2'' and C-
6''), 129.9 (C-6), 139.6 (C-2), 146.6 (C-4a), 150.5 (C-3a) 151.8 (C-9), 158.6 (C- 4''). 
[ESI-HRMS] calculated for C18H18N5O4: 368.1359 [M-H]+. Found: 368.1349 [M-H]+. 
4.2.1.7. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-(4-methoxyphenyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (9g). Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-
1-(4-methoxyphenyl)ethanone (8g) (0.24 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 97.5:2.5 to 87:13 v/v to give the product 
as a white solid. Yield: 0.24 g (79%), m.p. 202-203 oC, TLC (CH2Cl2-MeOH 9:1 v/v) 
Rf 0.45. 1H-NMR (DMSO-d6): δ 1.51 (septet, 1H, J=6.0 Hz, H-3'), 1.81 (q, 2H, J=7.0 
Hz, H-2'), 3.39 and 3.46 (two quint, 4H, J=5.5 Hz, H-4'), 3.81 (s, 3H, OCH3), 4.17 (t, 
2H, J=7.5 Hz, H-1'), 4.47 (t, 2H, J= 5.2 Hz, 2 x OH), 7.04 (d, 2H, J=8.0 Hz, H-3" and 
H-5"), 7.85 (d, 2H, J=8.0 Hz, H-2" and H-6"), 7.95 (s, 1H, H-2), 8.07 (s, 1H, H-7), 
12.97 (br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 29.1 (C-2'), 41.3 (C-3'), 42.0 (C-1'), 
55.8 (OCH3), 61.8 (C-4'), 102.2 (C-7), 115.0 (C-3" and C-5"), 116.1 (C-9a), 120.9 (C-
1"), 127.0 (C-2" and C-6"), 129.4 (C-6), 139.5 (C-2), 146.7 (C-4a), 150.5 (C-3a), 151.8 
(C-9), 160.1 (C-4"). [ESI-HRMS] calculated for C19H22N5O4: 384.1666 [M+H]+. 
Found: 384.1666 [M+H]+. 
4.2.1.8. 6-(4-Ethoxyphenyl)-3-(4-hydroxy-3-(hydroxymethyl)butyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (9h). Prepared from PCV (0.2 g, 0.8 mmol) and 2-bromo-
1-(4-ethoxyphenyl)ethanone (8h) (0.25 g, 1.04 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 91:9 v/v to give the product as a 
pale yellow solid. Yield: 0.24 g (77%), m.p. 276-278 oC, TLC (CH2Cl2-MeOH 9:1 v/v) 
Rf 0.5. 1H-NMR (DMSO-d6): δ 1.35 (t, 3H, J= 7.0 Hz, CH3), 1.51 (septet, 1H, J=6.0 
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Hz, H-3'), 1.82 (q, 2H, J=7.0 Hz, H-2'), 3.39 and 3.46 (two quint, 4H, J=5.5 Hz, H-4'), 
4.08 (q, 2H, J= 7.0 Hz, OCH2), 4.17 (t, 2H, J=7.0 Hz, H-1'), 4.44 (br s, 2H, 2 x OH), 
7.02 (d, 2H, J= 8.3 Hz, H-3" and H-5"), 7.83 (d, 2H, J= 8.3 Hz, H-2" and H-6"), 7.94 
(s, 1H, H-2), 8.05 (s, 1H, H-7), 12.93 (br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 15.1 
(CH3), 29.2 (C-2'), 41.4 (C-3'), 42.0 (C-1'), 61.8 (C-4'), 63.7 (OCH2), 102.1 (C-7), 115.4 
(C-3" and C-5"), 116.1 (C-9a), 120.8 (C-1"), 127.0 (C-2" and C-6"), 129.4 (C-6), 140.0 
(C-2), 146.7 (C-4a), 150.5 (C-3a), 151.8 (C-9), 159.4 (C-4"). [ESI-HRMS] calculated 
for C20H22N5O4: 396.1672 [M-H]+, Found: 396.1668 [M-H]+. 
4.2.1.9. 6-(Benzo[d][1,3]dioxol-5-yl)-3-(4-hydroxy-3-(hydroxymethyl)butyl)-3,5-
dihydro-9H-imidazo[1,2-a]purin-9-one (9i).Prepared from PCV (0.2 g, 0.8 mmol) and 
1-(benzo[d][1,3]dioxol-5-yl)-2-bromoethanone (8i) (0.25 g, 1.04 mmol) and purified 
by flash column chromatography eluting with CH2Cl2-MeOH-acetone 80:10:10 v/v/v 
to give the product as a pale yellow solid. Yield: 0.21 g (68%), m.p. 259-260 oC, TLC 
(CH2Cl2-MeOH 9:1 v/v) Rf 026. 1H-NMR (DMSO-d6): δ 1.51 (septet, 1H, J=6.0 Hz, 
H-3'), 1.82 (q, 2H, J=7.0 Hz, H-2'), 3.38 and 3.46 (two quint, 4H, J=5.5 Hz, H-4'), 4.17 
(t, 2H, J=7.5 Hz, H-1') 4.45 (t, 2H, J= 5.2 Hz, 2 x OH), 6.09 (s, 2H, H-2''), 7.03 (d, 1H, 
J= 8.1 Hz, H-7''), 7.41 (dd, 1H, J= 1.8, 8.1 Hz, H-6''), 7.53 (d, 1H, J= 1.7 Hz, H-4''), 
7.94 (s, 1H, H-2), 8.11 (s, 1H, H-7), 12.92 (br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 
29.2 (C-2'), 41.4 (C-3'), 42.0 (C-1'), 61.8 (C-4'), 101.9 (C-2''), 102.8 (C-7), 106.0 (C-
4''), 109.2 (C-7''), 116.1 (C-9a), 119.5 (C- 6''), 122.4 (C-5''), 129.3 (C-6), 139.6 (C-2), 
146.7 (C-4a), 148.2 (C-7a''), 148.5 (C-3a''), 150.6 (C-3a) 151.8 (C-9). [ESI-HRMS] 
calculated for C19H20N5O5: 398.1459 [M+H]+. Found: 398.1460 [M+H]+. 
4.2.1.10. 3-(4-Hydroxy-3-(hydroxymethyl)butyl)-6-(4-phenoxyphenyl)-3,5-dihydro-
9H-imidazo[1,2-a]purin-9-one (9j).Prepared from PCV (0.2 g, 0.8 mmol) and 2-
bromo-1-(4-phenoxyphenyl)ethanone (8j) (0.3 g, 1.04 mmol) and purified by flash 
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column chromatography eluting with CH2Cl2-MeOH 100:0 to 92:8 v/v to give the 
product as a white solid. Yield: 0.26 g (75%), m.p. 278-280 oC, TLC (CH2Cl2-MeOH 
9:1 v/v) Rf 0.53. 1H-NMR (DMSO-d6): δ 1.52 (septet, 1H, J=6.0 Hz, H-3'), 1.82 (q, 2H, 
J=7.0 Hz, H-2'), 3.38 and 3.46 (two quint, 4H, J=5.5 Hz, H-4'), 4.18 (t, 2H, J= 7.5 Hz, 
H-1'), 4.44 (br s, 2H, 2 x OH), 7.09 (d, 4H, J= 8.1 Hz, H-3'', H-5'', H-2''' and H-6'''), 
7.20 (t, 1H, J= 7.4 Hz, H-4'''), 7.44 (t, 2H, J=8.0 Hz, H-3''' and H-5'''), 7.93 (d, 2H, J= 
8.8 Hz, H- 2" and H-6"), 7.98 (s, 1H, H-2), 8.14 (s, 1H, H-7), 13.04 (br.s, 1H, H-5). 
13C-NMR (DMSO-d6): δ 29.1 (C-2'), 41.4 (C-3'), 42.0 (C-1'), 61.8 (C-4'), 103.1 (C-7), 
115.9 (C-9a), 119.2 and 119.6 (C-3", C-5", C-2''' and C-6'''), 123.6 (C-1"), 124.5 (C-
4'''), 127.4 and 130.7 (C-2", C-6", C-3''' and C-5'''), 129.0 (C-6), 139.5 (C-2), 146.8 (C-
4a), 150.6 (C-3a), 151.7 (C-9), 156.5 and 157.7 (C- 4" and C-1'''). [ESI-HRMS] 
calculated for C24H22N5O4:444.1672 [M-H]+, Found: 444.1675 [M-H]+. 
4.2.1.11. 3-(4-Hydroxybutyl)-6-phenyl-3,5-dihydro-9H-imidazo[1,2-a]purin-9-
one (10a). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(phenyl)ethan-1-one 
(8a) (0.23 g, 1.17 mmol) and purified by flash column chromatography eluting with 
CH2Cl2-MeOH 95:5 to 93:7 v/v to give the product as a white solid. Yield: 0.18 g 
(61%), m.p. 248-250 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 0.32. 1H-NMR (DMSO-
d6): δ 1.43 (quint., 2H, J=7.0 Hz, H-3'), 1.85 (quint, 2H, J= 7.0 Hz, H- 2'), 3.42 (q, 2H, 
J= 5.5 Hz, H-4'), 4.11 (t, 2H, J=7.2 Hz, H-1'), 4.49 (t, 1H, J= 4.8 Hz, OH), 7.39 (t, 1H, 
J= 7.4 Hz, H-4"), 7.48 (t, 2H, J= 7.7 Hz, H-3" and H-5"), 7.91 (d, 2H, J= 7.6 Hz, H-2'' 
and H-6''), 7.95 (s, 1H, H-2), 8.22 (s, 1H, H-7), 13.07 (br.s, 1H, H-5). 13C-NMR 
(DMSO-d6): δ 26.7 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 103.6 (C-7), 116.1 (C-
9a), 125.4 (C-4''), 128.5 (C-6), 129.2 (C-2'' and C-6''), 129.4 (C-1''), 129.5 (C-3'' and C-
5''), 139.7 (C-2), 146.9 (C-4a), 150.9 (C-3a), 151.8 (C-9). [ESI-HRMS] calculated for 
C17H28N5O2: 322.1309 [M+H]+. Found: 322.1302 [M+H]+. 
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4.2.1.12. 6-(4-Fluorophenyl)-3-(4-hydroxybutyl)-3,5-dihydro-9H-imidazo[1,2-
a]purin-9-one (10b). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(4-
fluorophenyl)ethanone (8b) (0.25 g, 1.17 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 100:0 to 94:6 v/v to give the product as a 
white solid. Yield: 0.19 g (62%), m.p. 288-290 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
0.31. 1H-NMR (DMSO-d6): δ 1.43 (quint, 2H, J=7.5 Hz, H-3'), 1.85 (quint, 2H, J= 7.5 
Hz, H-2'), 3.42 (q, 2H, J=5.4 Hz, H-4'), 4.11 (t, 2H, J=7.0 Hz, H-1'), 4.49 (t, 1H, J= 5.0 
Hz, OH), 7.34 (t, 2H, JHF = 8.9 Hz, H-3'' and H-5''), 7.96 (dd, 2H, JHF = 5.0, 9.0 Hz, H-
2" and H-6"), 7.96 (s, 1H, H-2), 8.22 (d, 1H, J= 2.0 Hz, H-7), 13.09 (br.s, 1H, H-5). 
13C-NMR (DMSO-d6): δ 26.7 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 103.6 (C-7), 
116.1 (C-9a), 116.6 (d, 2C, JCF = 22.6 Hz, C-3'' and C-5''), 125.1 (d, 1C, J= 3.8 Hz, C-
1''), 127.7 (d, 2C, J= 7.5 Hz, C-2'' and C-6''), 128.5 (C-6), 139.7 (C- 2), 146.8 (C-4a), 
150.7 (C-3a), 151.8 (C-9), 162.6 (d, 1C, J= 246.5 Hz, C-4''). 19F-NMR(DMSO-d6): δ-
112.40.[ESI-HRMS] calculated for C17H17N5O2F: 342.1366 [M+H]+. Found: 342.1373 
[M+H]+. 
4.2.1.13. 6-(4-Chlorophenyl)-3-(4-hydroxybutyl)-3,5-dihydro-9H-imidazo[1,2-
a]purin-9-one (10c). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(4-
chlorophenyl)ethanone (8c) (0.27 g, 1.17 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 92:8 v/v to give the product as a 
white solid. Yield: 0.2 g (62%), m.p. 280-282 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
0.36. 1H-NMR (DMSO-d6): δ 1.43 (quint, 2H, J = 7.0 Hz, H-3'), 1.85 (quint, 2H, J= 
7.5 Hz; H-2'), 3.42 (q, 2H, J=5.5 Hz, H-4'), 4.10 (t, 2H, J=7.0 Hz, H-1'), 4.48 (t, 1H, J= 
5.0 Hz, OH), 7.53 (d, 2H, J= 8.4 Hz, H-2" and H-6"), 7.92 (d, 2H, J= 8.4 Hz, H-3'' and 
H-5''), 7.94 (s, 1H, H-2), 8.27 (s, 1H, H-7), 14.00 (br.s, 1H, H-5). 13C-NMR (DMSO-
d6): δ 26.7 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 104.3 (C-7), 116.1 (C-9a), 127.1 
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(C-2'' and 6''), 127.4 (C-1''), 128.3 (C-6), 129.5 (C-3'' and C-5''), 133.6 (C-4''), 139.7 
(C-2), 146.9 (C-4a), 150.7 (C-3a), 151.7 (C-9).[ESI-HRMS] calculated for 
C17H17N5O2Cl: 358.1071 [M+H]+. Found: 358.1075 [M+H]+. 
4.2.1.14. 3-(4-Hydroxybutyl)-6-(p-tolyl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one 
(10d). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(p-tolyl)ethanone (8d) 
(0.25 g, 1.17 mmol) and purified by flash column chromatography eluting with CH2Cl2-
MeOH 100:0 to 94:6 v/v to give the product as a white solid. Yield: 0.2 g (67%), m.p. 
260-261 oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 0.63. 1H-NMR (DMSO-d6): δ 1.43 
(quint, 2H, J=7.0 Hz, H-3'), 1.85 (quint, 2H, J= 7.5 Hz, H-2'), 2.34 (s, 3H, CH3), 3.42 
(q, 2H, J=5.5 Hz, H-4'), 4.11 (t, 2H, J=7.2 Hz, H-1'), 4.49 (t, 1H, J= 5 Hz, OH), 7.28 
(d, 2H, J= 8.0 Hz, H-3'' and H-5''), 7.79 (d, 2H, J= 8.2 Hz, H-2" and H-6"), 7.95 (s, 1H, 
H-2), 8.14 (s, 1H, H-7), 13.01 (br.s, 1H, H- 5). 13C-NMR (DMSO-d6): δ 21.3 (CH3), 
26.7 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 103.0 (C-7), 116.0 (C-9a), 125.4 (C-3'' 
and 5''), 125.6 (C-1''), 129.5 (C- 6), 130.1 (C-2'' and C-6''), 138.8 (C-4''), 139.6 (C-2), 
146.8 (C-4a), 150.6 (C- 3a), 151.8 (C-9). [ESI-HRMS] calculated for C18H20N5O2: 
338.1617 [M+H]+. Found: 338.1626 [M+H]+. 
4.2.1.15. 3-(4-Hydroxybutyl)-6-(4-(trifluoromethyl)phenyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (10e). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-
1-(4-(trifluoromethyl)phenyl)ethanone (8e) (0.3 g, 1.17 mmol)  and purified by flash 
column chromatography eluting with CH2Cl2-MeOH 97.5:2.5 to 92:8 v/v to give the 
product as a white solid. Yield: 0.25 g (71%), m.p. 292-293 oC, TLC (CH2Cl2-MeOH 
95:5 v/v) Rf 0.58. 1H-NMR (DMSO-d6): δ 1.44 (quint, 2H, J=7.0 Hz, H-3'), 1.86 (quint, 
2H, J= 7.5 Hz, H-2'), 3.43 (q, 2H, J=5.5 Hz, H-4'), 4.12 (t, 2H, J=7.0 Hz, H-1'), 4.45 (t, 
1H, J= 5.0 Hz, OH), 7.84 (d, 2H, J= 8.0 Hz, H-2'' and H-6''), 7.96 (s, 1H, H-2), 8.14 (d, 
2H, J= 8.0 Hz, H-3" and H-5"), 8.42 (s, 1H, H-7), 13.23 (br.s, 1H, H-5). 13C-NMR 
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(DMSO-d6): δ 26.7 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 105.7 (C-7), 116.1 (C-
9a), 124.5 (d, 1C, J= 272.0 Hz, CF3), 126.0 (C-2'' and C-6''), 126.4 (d, 2C, J= 3.6 Hz, 
C-3'' and C-5''), 128.0 (C-6), 128.5 (q, 1C, JCF = 32.0 Hz, C-4''), 132.6 (C-1''), 139.8 
(C-2), 147.1 (C-4a), 150.8 (C-3a), 151.7 (C-9). 19F-NMR(DMSO-d6): δ -61.14. Anal. 
Calcd for C18H16F3N5O20.5H2O (400.1309): C, 54.00; H, 2.38; N, 17.49. Found: C, 
53.56; H, 3.84; N, 17.33. 
4.2.1.16. 3-(4-Hydroxybutyl)-6-(4-methoxyphenyl)-3,5-dihydro-9H-imidazo[1,2-
a]purin-9-one (10f). Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(4-
methoxyphenyl)ethanone (8g) (0.27 g, 1.17 mmol) and purified by flash column 
chromatography eluting with CH2Cl2-MeOH 95:5 to 93:7 v/v to give the product as a 
white solid. Yield: 0.19 g (61%), m.p. 252-254oC, TLC (CH2Cl2-MeOH 95:5 v/v) Rf 
0.23. 1H-NMR (DMSO-d6): δ 1.43 (quint, 2H, J=7.0 Hz, H-3'), 1.85 (quint, 2H, J= 7.5 
Hz; H-2'), 3.42 (q, 2H, J=5.4 Hz, H-4'), 3.81 (s, 3H, OCH3) 4.11 (t, 2H, J=7.0 Hz, H-
1'), 4.48 (t, 1H, J= 5.0 Hz, OH), 7.04 (d, 2H, J= 8.8 Hz, H-3" and 5''), 7.84 (d, 2H, J= 
8.8 Hz, H-2" and H-6"), 7.94 (s, 1H, H-2), 8.08 (s, 1H, H-7), 12.97 (br.s, 1H, H-5). 13C-
NMR (DMSO-d6): δ 26.7 (C-2'), 30.1 (C-3'), 43.5 (C-1'), 55.7 (OCH3), 60.6 (C-4'), 
102.2 (C-7), 115.0 (C-3'' and C-5''), 116.0 (C-9a), 120.9 (C-1''), 126.9 (C-2'' and C-6''), 
129.4 (C-6), 139.6 (C-2), 146.7 (C-4a), 150.5 (C-3a), 151.8 (C-9), 160.1 (C-4'').  [ESI-
HRMS] calculated for C18H20N5O3: 354.1566 [M+H]+. Found: 354.1563 [M+H]+. 
4.2.1.17. 6-(Benzo[d][1,3]dioxol-5-yl)-3-(4-hydroxybutyl)-3,5-dihydro-9H-
imidazo[1,2-a]purin-9-one (10g). Prepared from HBG (0.2 g, 0.9 mmol) and 1-
(benzo[d][1,3]dioxol-5-yl)-2-bromoethanone (8i) (0.28 g, 1.17 mmol) and purified by 
flash column chromatography eluting with CH2Cl2-MeOH 97.5:2.5 to 92:8 v/v to give 
the product as a pale yellow solid. Yield: 0.23 g (69%), m.p. 272-274oC, TLC (CH2Cl2-
MeOH 95:5 v/v) Rf 0.38. 1H-NMR (DMSO-d6): δ 1.43 (quint, 2H, J=7.5 Hz, H-3'), 
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1.85 (quint, 2H, J= 7.5 Hz; H-2'), 3.42 (q, 2H, J=5.5 Hz, H-4'), 4.11 (t, 2H, J=7 Hz, H-
1'), 4.45 (t, 1H, J= 5 Hz, OH), 6.09 (s, 1H, H-2''), 7.03 (d, 1H, J= 8.2 Hz, H-7''), 7.41 
(d, 1H, J= 8.1 Hz, H-6"), 7.53 (s, 1H, H-4''), 7.93 (s, 1H, H-2), 8.12 (s, 1H, H-7), 12.92 
(br.s, 1H, H- 5). 13C-NMR (DMSO-d6): δ 26.7 (C-2'), 30.1 (C-3'), 43.5 (C-1'), 60.7 (C- 
4'), 101.9 (C-2''), 102.8 (C-7), 106.0 (C-4''), 109.2 (C-7''), 116.0 (C-9a), 119.4 (C-6''), 
122.5 (C-5''), 129.4 (C-6), 139.9 (C-2), 146.7 (C-4a), 148.2 (C-7a''), 148.5 (C-3a''), 
150.6 (C-3a), 151.8 (C-9). Anal. Calcd for C18H17N5O40.3H2O (372.5312): C, 58.00; 
H, 4.76; N, 18.79. Found: C, 57.60; H, 4.37; N, 18.56. 
4.2.1.18. 3-(4-Hydroxybutyl)-6-(thiophen-2-yl)-3,5-dihydro-9H-imidazo[1,2-
a]purin-9-one (10h).Prepared from HBG (0.2 g, 0.9 mmol) and 2-bromo-1-(thiophen-
2-yl)ethanone (8k) (0.24 g, 1.17 mmol) and purified by flash column chromatography 
eluting with CH2Cl2-MeOH 95:5 to 92:8 v/v to give the product as a pale yellow solid. 
Yield: 0.19 g (64%), m.p. 246-247oC, TLC (CH2Cl2-MeOH 9:1 v/v) Rf 0.67. 1H-NMR 
(DMSO-d6): δ 1.43 (quint., 2H, J=7.0 Hz, H-3'), 1.85 (quint, 2H, J= 7.5 Hz; H-2'), 3.42 
(q, 2H, J=5.5 Hz, H-4'), 4.11 (t, 2H, J=7.0 Hz, H-1'), 4.45 (t, 1H, J= 5.0 Hz, OH), 7.18 
(t, 1H, J= 4.2 Hz, H-4''), 7.61 (d, 1H, J= 3.3 Hz, H-3''), 7.66 (d, 1H, J= 4.9 Hz, H-5''), 
7.91 (s, 1H, H-2), 7.95 (s, 1H, H-7), 13.14 (br.s, 1H, H-5). 13C-NMR (DMSO-d6): δ 
26.6 (C-2'), 30.0 (C-3'), 43.5 (C-1'), 60.6 (C-4'), 102.7 (C-7), 116.1 (C-9a), 124.6 (C-
6), 126.6 (C-3''), 127.5 (C-4''), 128.6 (C-5''), 139.7 (C-2), 146.5 (C-4a), 150.6 (C-3a), 
151.7 (C-9). [ESI-HRMS] calculated for C15H16N5O2S: 330.1019 [M+H]+. Found: 
330.1021 [M+H]+. 
4.3. Antiviral and Cytotoxicity assays 
The antiviral assays were based on inhibition of virus-induced cytopathicity or plaque 
formation in HEL [herpes simplex virus 1 (HSV-1) (KOS), HSV-2 (G), vaccínia virus, 
vesicular stomatitis virus, cytomegalovirus (HCMV), varicella-zoster virus (VZV), 
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adenovirus-2, and human corona virus (299E)], Vero (para-influenza-3, reovirus-1, 
Sindbisvirus, and Coxsackie B4), HeLa (vesicular stomatitis virus, Coxsackie virus B4, 
and respiratorysyncytial virus), or MDCK [influenza A (H1N1; H3N2) and influenza 
B] cell cultures. Confluent cell cultures (or nearly confluent for MDCK cells) in 
microtiter 96-well plates were inoculated with 100 CCID50of virus (1 CCID50 being the 
virus dose to infect 50% of the cell cultures) or with 20 plaque- forming units (PFU). 
After 1–2h virus adsorption period, residual virus was removed, and the cell cultures 
were incubated in the presence of varying concentrations (200, 40, 8, 1.6, 0.32 M) of 
the test compounds. Viral cytopathicity was recorded as soon as it reached completion 
in the control virus-infected cell cultures that were not treated with the test compounds. 
Antiviral activity was expressed as the EC50 (50% effective concentration) or 
compound concentration required to reduce virus-induced cytopathogenicity or viral 
plaque formation by 50%. The MCC (minimal cytotoxic concentration) values were 
determined as the compound concentration required to afford a microscopically visible 
alteration of cell morphology. The new compounds were screened for their potential 
cytostatic activity against eight human cancer cell lines. The 50% cytostatic inhibitory 
concentration (IC50) causing a 50% decrease in cell proliferationrelative to the number 
of cells in the untreated controls was determined against retina (non cancerous) hTERT 
RPE-1, pancreatic adenocarcinomaCapan-1, chronic myeloid leukaemia Hap1, lung 
carcinoma NCI-H460, acute lymphoblastic leukaemia DND-41, acute myeloid 
leukaemia HL-60, chronic myeloid leukaemia K-562 and non-Hodgkin lymphoma Z-
138.  
 
4.4.Molecular modelling 
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Docking studies were performed using the MOE18 crystal structure of HSV-1 thymidine 
kinase co-crystallised with PCV (PDB 1KI3)19 and 9-(4-hydroxybutyl)-N2-
phenylguanine (HBPG) (PDB 1QHI)20. All minimisations were performed with MOE 
until a RMSD gradient of 0.01 Kcal/mol/A with the MMFF94 forcefield and partial 
charges were automatically calculated. The Alpha Triangle placement, which derives 
poses by random superposition of ligand atom triplets through alpha sphere dummies 
in the receptor site, was chosen to determine the poses. The London G scoring 
function estimates the free energy of binding of the ligand from a given pose. 
Refinement of the results was done using the MMFF94 forcefield, and rescoring of the 
refined results using the London G scoring function was applied. The output database 
dock file was created with different poses for each ligand and arranged according to the 
final score function (S), which is the score of the last stage that was not set to zero. 
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